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CRITICAL PERSPECTIVE
n Summary The role of endo-
myocardial biopsies in patients
with clinically suspected acute
myocarditis, myocarditis in the
past, and dilated cardiomyopathy
is discussed controversially. In
fact, it is still under discussion
whether information obtained
from endomyocardial biopsies is
relevant for further clinical deci-
sions. Therefore this Critical Per-
spective will deal with the ques-
tion, which patient should under-
go endomyocardial biopsy investi-
gations for an etiopathogenic dif-
ferentiation of the disease and for
the possible choice of immuno-
modulatory treatment strategies.
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Introduction
The indication for endomyocardial biopsies (EMBs)
in patients with clinically suspected acute myocardi-
tis, myocarditis in the past, or dilated cardiomyopa-
thy (DCM) is still being discussed controversially.
One major reason is that no evidence-based guide-
lines exist to perform endomyocardial biopsies in
these patients.
It is essential to differentiate between the acute
(clinically suspected acute myocarditis) and the
chronic phase of the disease (clinically suspected
myocarditis in the past or DCM). In addition, it is
important to emphasize that a differentiation be-
tween clinically based diagnosis and endomyocardial
biopsy (EMB) proven diagnosis has to be taken into
account, because there are no clinical symptoms –
especially in the chronic phase of the disease – that
correlate with the EMB results.
A detailed analysis of EMBs using contemporary
diagnostic tools (exact characterization of the myo-
cardial inflammation (histology according to Dallas
classification, immunohistology) and of the viral
persistence (molecular biological approach using
polymerase chain reaction/PCR) is pertinent for the
exact etiopathogenic differentiation [3, 9, 29, 31–33,
Abbreviations
BICC-Trial Betaferon® in Chronic Viral Cardiomyopathy
CK Creatinine kinase
DCM Dilated cardiomyopathy
DCMi Inflammatory cardiomyopathy
ECG Electrocardiogram
EMB Endomyocardial biopsy
LV Left ventricle
PCR Polymerase chain reaction
TIMP Tissue inhibitors of matrix metalloproteinases39, 46–48, 50, 52, 56]. Histological assessment ac-
cording to the Dallas classification enables the differ-
entiated diagnosis of myocarditis (cellular infiltra-
tion combined with myocyte necrosis with or with-
out fibrosis; Fig. 1) and of borderline myocarditis
(cellular infiltration without myocyte necrosis with
or without fibrosis). Once the diagnosis of myocar-
ditis has been made in endomyocardial specimens,
patients may be followed by repeat biopsy, especially
if no improvement in left ventricular function is ob-
served. In addition, if an unequivocal diagnosis of
myocarditis has been made in a previous EMB, such
terms as ongoing (persistent), resolving (healing), or
resolved (healed) myocarditis with or without fibro-
sis in conjunction with the clinical course of the pa-
tient can be used to indicate progression or regres-
sion of disease [3]. In patients with global (left ven-
tricular ejection fraction/LVEF <50%) or moderately
impaired persistent LV dysfunction with locoregional
wall motion abnormalities (LVEF >50%) and with-
out histologically diagnosed myocarditis respectively
borderline myocarditis according to the Dallas clas-
sification, further work-up concerning low grade
myocardial inflammation and viral persistence is in-
dicated. A more sensitive work-up for myocardial in-
flammation should be undertaken using highly sen-
sitive immunohistological techniques for the detec-
tion of the low grade inflammation often seen in the
chronic phase of disease consistent with inflamma-
tory cardiomyopathy (DCMi) [56]. This low grade
inflammation is, however, difficult to establish by
conventional histology according to the Dallas crite-
ria because the cellular infiltrates are often sparse
and may be missed by sampling error. It is also dif-
ficult to distinguish between non-inflammatory cells
(e.g., fibroblasts or pericytes) and infiltrating lym-
phocytes. By using immunohistological techniques, a
more accurate identification of cellular infiltrates
and other immune markers expressed in an active
immunological process like cell adhesion molecules
(e.g., intercellular cell adhesion molecule-1/ICAM-1,
vascular cell adhesion molecule-1/VCAM-1) is feasi-
ble [5, 31, 48]. In addition, using higly sensitive mo-
lecularbiological tools, viral persistence can be diag-
nosed in these patients in high frequency. These dif-
ferent diagnostic tools, enable a classification of pa-
tients with inflammatory cardiomyopathy (DCMi:
with immunohistologically proven myocardial in-
flammation in association with cardiac dysfunction
according to the WHO Classification of Cardiomyo-
pathies 1995) [39, 56] with and without viral persis-
tence, in patients with viral persistence without myo-
cardial inflammation, and in patients with idiopathic
DCM based on genetic factors, healed myocarditis in
the past, or storage diseases (e.g., amyloidosis;
Fig. 2) [56] has to be considered on a case-by-case
basis.
In patients with clinically suspected acute viral
induced myocarditis, there is no definitive clinical
indication to perform EMBs, because there are no
data that an early specific treatment has any benefit
concerning duration of the disease or improvement
of heart failure. In addition, this disease has a quite
good prognosis, because in about 80% of these pa-
tients a complete healing is observed [13]. However,
in cases with progressive LV dysfunction of un-
known cause despite complete heart failure medica-
tion, there is a need to perform EMB to verify the
clinically suspected diagnosis of acute viral myocar-
ditis and to rule out rare causes (e.g., giant cell myo-
carditis, eosinophilic myocarditis) for rapid progres-
sion of LV dysfunction with possible fatal course [1,
10–12, 15–17, 19, 23, 30, 49, 65, 68].
In contrast to the very early stage of acute myo-
carditis, the majority of EMB-based treatment trials
were performed in patients with a more chronic
course of disease like clinically suspected DCM.
Therefore, in this stage of disease patients may bene-
fit from a EMB-based diagnosis with respect to
prognosis [35] and possible choice of rational treat-
ment strategies (immunosuppression, antiviral treat-
ment) (Fig. 4) based on monocentric or pilot trials
[34, 36, 60, 69]. The approach of immunosuppres-
sion in patients with EMB proven myocardial in-
flammation without viral persistence has demon-
strated beneficial effects of heart failure symptoms
and LV function parameters [36, 69, 70], while ad-
verse outcome of immunosuppression in virus posi-
tive patients has been reported [20]. The attempt of
an antiviral treatment strategy is based on the
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Fig. 1 Myocarditis according to the Dallas classification. Focal lymphomono-
nuclear infiltrates with adjacent myocytolysis (myocarditis; original magnifica-
tion ×200). Reproduced from [53]known adverse prognostic impact of viral persis-
tence with respect to the natural process of LV func-
tion and mortality [35]. An antiviral pilot trial with
interferon- demonstrated complete elimination of
viral genomes in patients with adenoviral or entero-
viral persistence, accompanied by a significant ame-
lioration of clinical symptoms and significant im-
provement of LV function [34]. Based on these en-
couraging results, a prospective, placebo-controlled,
multicenter, randomized phase II study (Betaferon®
in Chronic Viral Cardiomyopathy – BICC Trial) is
currently evaluating the clinical benefit of an inter-
feron- therapy in patients with viral persistence.
Therefore, only a detailed analysis of EMBs con-
cerning myocardial inflammation and viral persis-
tence, respectively, allows the etiopathogenic differ-
entiation and an implementation of causal treatment
strategies in the context of clinical trials. This EMB-
based approach may lead to improved patient man-
agement in the future.
This Critical Perspective will therefore deal with
the question, which patients with clinically suspected
acute myocarditis, clinically suspected myocarditis
in the past, and DCM of unknown cause should un-
dergo EMB investigations for an etiopathogenic dif-
ferentiation of the disease and for the possible
choice of immunomodulatory treatment strategies.
Background
n Etiology of acute myocarditis
Acute myocarditis is most often caused by cardiotro-
pic viral infections. As such, enteroviruses, particu-
larly coxsackieviruses and adenoviruses, are known
[9, 32, 49, 52]. An important step concerning the un-
derstanding of the molecular basis of cardiotropic
viral infection was achieved by the studies analyzing
the relevance of the coxsackievirus-adenovirus re-
ceptor (CAR) in this disease entity [45, 55]. In addi-
tion to enteroviruses and adenoviruses, recent inves-
tigations have shown that genomes of parvovirus
B19, human herpes virus type 6, hepatitis C and Ep-
stein-Barr virus are detected even more frequently
in the myocardium of patients presenting with acute
myocarditis [29, 33]. Interestingly, all these various
cardiotropic viruses can be detected in patients with
the clinically suspected diagnosis of DCM as well
[20, 32]. With respect to enteroviruses, several
pathomechanisms can contribute to the impairment
and progression of LV function. These can be classi-
fied as direct virus-mediated and indirect virus-in-
duced mechanisms. One recently elucidated direct
virus-mediated effect is the cleavage of dystrophin
by the enterovirus protease A2, thereby interfering
with an essential part of the cardiomyocyte cytoskel-
eton responsible for force transmission [4]. Further-
more, even non-replicative intermediates of entero-
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Fig. 2 Cardiac amyloidosis: a Cardiac amyloidosis (H&E staining), b in po-
larized light, the Kongo red staining depicts amyloid fibrils at the surface
and between cardiac myocytes, c same staining as b. In depolarized light,
the amyloid fibrils can be identified as bright tissue areas
a
b
cviruses can cause an impairment of LV function in
animal models [66]. Major virus-induced effects are
exerted during the immune response to infection,
which aims at viral elimination. Both lymphocytes
and macrophages, the infiltration of which is
mediated by the enhanced expression of cell adhe-
sion molecules [46, 48], are involved in the course of
the intramyocardial antiviral immune response. This
cellular myocardial infiltration is linked to an in-
creased expression of cytokines, which are known to
impair LV function, e.g., tumor necrosis factor-
(TNF-) [41, 63]. These pathogenic mechanisms in-
volved in myocarditis and DCMi are summarized in
Fig. 3.
Apart from viruses, bacteria, rickettsia, spirochae-
ta and fungi can be detected in special cases in pa-
tients presenting with clinically suspected acute
myocarditis [23, 25]. A typical non-viral induced in-
fection of the heart is caused by borrelia burgdor-
feri, which may preferentially interfere with the con-
duction system leading to conduction abnormalities
[62].
Non-infective causes of myocardial inflammation
and subsequent myocyte necrosis may be caused by
cardiotoxic agents such as doxorubicin, systemic dis-
eases with cardiac involvement (Lupus erythemato-
sus [68] or other collagenoses) and occasionally as a
consequence of a hypersensitivity reaction due to
different drugs [23]. The drug-induced hypersensi-
tivity reaction often presents as eosinophilic pancar-
ditis with infiltrating lymphocytes, pathognomonic
eosinophilic cells, plasma cells and histiocytes.
Giant cell myocarditis is another specific type of
acute myocarditis of unknown origin. Due to the
fatal prognosis, it is important to reach a defined
histological diagnosis for further specific treatment
approaches. The specific treatment approach in this
disease entity is mainly based on a registry of 63
cases of giant cell myocarditis. The 22 patients
treated with corticosteroids and cyclosporines,
azathioprine, or both therapies survived for an aver-
age of 12.3 months, as compared with an average of
3 months for the 30 patients who received no immu-
nosuppressive therapy (p<0.001). However, even
these promising data concerning immunosuppressive
therapy in these patients, heart transplantation is
the final treatment of choice for most patients so far
[10, 11]. In addition, it is very important to differ-
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Fig. 3 Pathophysiology of myocarditis and DCMientiate giant cell myocarditis from other forms of
granulomatous diseases like cardiac sarcoidosis, be-
cause otherwise no adequate specific treatment
approach can be initiated [10, 11, 49].
In rare cases, a hypersensitivity reaction caused
by different drugs [23] can lead to the clinical pic-
ture of a hypersensitivity myocarditis or eosinophilic
myocarditis. Histologically, this kind of myocarditis
shows a clear interstitial infiltration of eosinophiles,
in addition to lymphocytes, plasma cells and histio-
cytes, which mostly affect all sections of the heart in
the sense of a pancarditis, often only with non-sig-
nificant myocytolysis [27].
A further form of hypereosinophilic carditis is
Löffler’s endocarditis. In this scenario, hypereosino-
philia develops by various reasons and can cause
multiorganic failure (heart, lung, borne marrow,
brain). Mainly the endocardium is affected with bi-
ventricular endocardial thickening in the region of
the outflow tract as well as in the region of the apex
cordis [12].
n Etiology of inflammatory cardiomyopathy/DCMi
Inflammatory cardiomyopathy (DCMi) is defined as
a specific cardiomyopathy entity according to the re-
port of the WHO/ISFC Task Force on the Definition
and Classification of Cardiomyopathies 1995 [39,
56]. The diagnosis of DCMi is based on an exact
analysis of EMBs using an arsenal of procedures, in-
cluding histological, immunohistological, and virolo-
gical tools (especially PCR). The pathophysiological
concept of this disease entity is that myocardial in-
flammation and/or viral genomes may persist
chronically due to an inadequate immune response
after an acute viral induced myocarditis. This is con-
firmed by the fact that in patients with clinically
suspected DCM with a chronic progression of LV
dysfunction, viral persistence in the myocardium
(Fig. 4) as well as myocardial inflammation (Fig. 5)
can be detected in a high percentage in these pa-
tients [29, 31, 32, 47, 48, 50, 52]. In addition, this
concept of transition from acute myocarditis to
DCMi due to persiting low grade myocardial inflam-
mation with or without viral persistence is con-
firmed by the following known effects. Viral persis-
tence due to an inadequate immune response can
cause direct cytopathic effects (i.e., cleavage of dys-
trophin by the enteroviral protease A2 [4]) as well as
virus-induced anti-cardiac immune responses. If this
immune response is uncontrolled, it can result in T-
cell mediated anti-cardiac immunity, leading to pro-
gressive myocardial dysfunction and remodeling
[47, 48]. Beside the cellular immunity, antibody
linked immunity against myocardial proteins seems
to be important [42, 43 45]. Autoantibodies against
different myocardial antigens have been character-
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Fig. 4 Diagnostic and therapeutic algorithms in DCMized. In addition, cytokines per se like tumor necro-
sis factor  (TNF-), which have direct cardiodepres-
sive effects, are elevated [41, 63]. Furthermore, they
promote remodeling of the extracellular matrix by
inducing an imbalance in the system of metallopro-
teinases and their inhibitors (tissue inhibitors of ma-
trix metalloproteinases (TIMPs)) [37, 51, 54]. There-
fore, all these effects causing a progressive destruc-
tion of the myocardium can finally lead to the clini-
cal presentation of DCM. These pathogenic mecha-
nisms involved in myocarditis and DCMi are sum-
marized in Fig. 3.
n Clinical course and presentation
of acute myocarditis
The clinical course and presentation of acute myo-
carditis is highly variable. Presumably, a majority of
the viral-induced cases pass in a clinically inappar-
ent course. In some cases, however, fulminant
courses with rapidly progressing LV dysfunction oc-
cur, which necessitates maximal intensive care thera-
py (i.e., inotropic support and implantation of an as-
sist device) [21, 40, 53, 71]. Virus-caused impair-
ment of systolic and diastolic LV function [64] are
responsible for heart failure symptoms. Some pa-
tients may present with an acute coronary syn-
drome, including abrupt onset of angina, combined
with ECG changes (ST-elevation or T-wave inver-
sions) and increase of heart specific enzymes such
as troponin or creatinin kinase [33], often linked to
an antecedent flue-like illness period. Echocardio-
graphic analysis often reveals a variable degree of
LV dysfunction. A pericardial effusion (perimyocar-
ditis) may be present during the acute stage of dis-
ease. A similar variability of complaints and sponta-
neous courses is also seen in non-infectious acute
myocarditis [10].
n Clinical course and presentation
of inflammatory cardiomyopathy/DCMi
After the acute phase of the virus-induced acute
myocarditis, approximately 20% of these patients de-
velop a chronically progressive disease consistent
with the clinical picture of DCM [13]. Because this
transition is a highly dynamic course and not pre-
dictable, it is clinically impossible to decide, if acute
myocarditis will heal, and whether intramyocardial
inflammation or viral persistence will persist chroni-
cally in these patients. In addition, there are no clin-
ical predictors that allow the identification of pa-
tients at risk of developing chronic progressive dis-
ease. So far, only by a detailed analysis of EMBs can
a definitive diagnosis of DCMi (myocardial inflam-
mation with or without viral persistence) be made,
which has an impact on prognosis and initiation of
rational treatment strategies (immunomodulation,
antiviral) (Fig. 4).
Critical debate
PRO
n Clinical parameters are not useful
for the diagnosis of myocardial inflammation
or virus persistence
Clinical presentation with pericardial effusion, ECG
changes, elevation of cardiac specific enzymes (e.g.,
troponin-T, CK), or LV dysfunction in association
with an antecedent viral infection may be considered
as a relevant pathogen for the clinically suspected
diagnosis of acute myocarditis, or acute myocarditis
in the past, respectively. However, these clinical pa-
rameters are unspecific and do not substitute inves-
tigations of EMBs for myocardial inflammation or
virus persistence, since clinical parameters do not
correlate with myocardial inflammation with or
without viral persistence or with the prognosis of
the disease [32, 33]. In addition, the diagnosis of
myocardial inflammation and/or viral persistence in
patients with clinically suspected DCM is also im-
possible by using anamnestic or clinical data. How-
ever, the diagnosis of DCMi is based on the EMB
proven detection of myocardial inflammation with
or without viral persistence combined with an im-
pairment of LV function. Therefore, a possible virus
persistence or myocardial inflammation can only be
substantiated by extensive examinations of EMBs in
patients with clinically suspected myocarditis, myo-
carditis in the past and DCM. However, it should be
emphasized that all other factors causing an impair-
ment of LV function (e.g., coronary heart disease,
significant valvular disease, severe arterial hyperten-
sion, and diabetes-induced heart failure) have to be
excluded prior to EMB extraction.
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inflammation or viral persistence by a complete
diagnostic arsenal (histology, immunohistology
and virological analysis)
in specially certified laboratories
n Histology
Regarding myocardial inflammation, the histological
examination of EMBs according to the Dallas classi-
fication is predominantly suitable to detect high
grade inflammatory processes. According to the Dal-
las classification, these processes are defined as myo-
carditis (cellular infiltrates with myocyte necrosis
with or without fibrosis) (Fig. 1) or borderline myo-
carditis (cellular infiltrates without myocyte necro-
sis) [3]. Under additional consideration of the fol-
low-up EMB investigations and also the clinical
course of the patients, ongoing, healing or healed
myocarditis can be differentiated. Several studies
have shown that the sole histological assessment of
EMBs is unsuitable to detect especially low grade
myocardial inflammation due to low sensitivity and
specificity, sampling error and interobserver variabil-
ity [24, 31, 48, 59]. This problem of sampling error
is even enhanced in the acute stage of disease due to
the often described focal pattern of inflammation.
Hauck et al. demonstrated in post mortem tissue of
patients with histologically proven lymphocytic
myocarditis that with the evaluation of five biopsies,
the histological diagnosis of myocarditis/borderline
myocarditis showed false negative results in 55% of
the cases, and the correct diagnosis could be con-
firmed only in 45% of the analyzed EMBs [24].
Therefore, the Dallas criteria based on histological
analysis are not adequate to identify patients with
viral or autoimmune-related myocardial dysfunction
[5]. However, the histological analysis of EMBs is es-
sential in the diagnosis of fibrosis, hypertrophy, and
storage diseases. In addition, rare causes of myocar-
ditis-like giant cell myocarditis or eosinophilic myo-
carditis can only be diagnosed by the histological
analysis [1, 10, 11, 17, 21, 30]. Furthermore, other
forms of non-infectious myocarditis, i.e., the involve-
ment of the myocardium in connective tissue dis-
eases or in sarcoidosis can only be verified by histo-
logical analysis in combination with special immu-
nohistological stainings of EMBs [68].
n Immunohistology
Using immunohistochemical techniques, it is possi-
ble to elucidate intramyocardial inflammation quali-
tatively and quantitatively with a high sensitivity
and specificity compared to histological analysis ac-
cording to the Dallas classification. Immunohistolo-
gical evaluation offers the possibility of a phenotypic
characterization of immunocompetent infiltrates
such as lymphocytes and macrophages, as well as
cytotoxic (perforin-positive) cells. These cytotoxic T-
cells (CTL) are especially important since they are
specifically involved in the T-cell mediated cardio-
myocyte loss in DCMi [47]. Abundance of endotheli-
al cell adhesion molecules (CAMs) is clearly detect-
able in EMBs with increased lymphocytic and
macrophage infiltrates. There is a close association
between CAMs expression and especially counter-re-
ceptor positive infiltrates, substantiating the pivotal
role of endothelial CAMs expression for the transen-
dothelial migration of circulating immunocompetent
cells into the target organs [45]. In addition, the
homogenous CAMs expression pattern in the myo-
cardium (independent from the localization of infil-
trating cells) helps to reduce the sampling error sig-
nificantly, which implies that CAMs abundance per
se can be regarded as a relevant diagnostic approach
for DCMi even in the absence of infiltrates (Fig. 6)
[26, 48, 69, 70]. Moreover, exact quantification of the
myocardial inflammation can be carried out by digi-
tal image analysis systems in an observer-indepen-
dent manner [44, 45]. This qualitative and quantita-
tive analysis of the myocardial inflammatory process
cannot be performed following a mere histological
approach.
In conclusion, it should be pointed out that no
techniques other than histology or immunohistology
are suitable for the definitive diagnosis of myocar-
dial inflammation in virus-induced as well as in
noninfectious forms of myocarditis.
n Virological analysis
Only by the use of molecular biological techniques
(i.e., PCR, in situ hybridization) is it possible to de-
tect reliably viral genomes in the myocardium of pa-
tients presenting with myocarditis or DCM [9, 29,
32, 33, 50, 52]. Apart from the mere presence of vi-
ral genomes, the biological activity of viruses (active
replication versus viral latency) and the quantifica-
tion of the virus load can be evaluated in EMBs
solely by molecular biological methods [52, 64].
Concerning the analysis of biological activity, this
evaluation is demonstrated so far only in enteroviral
infection [52].
In general, the viral load of the myocardium has
to be quantified by realtime PCR. The respective
subtypes or cardiotropic viruses can be evaluated by
sequence analysis. In the future, specific subtypes of
cardiotropic viruses might gain special interest for
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analysis is also important as a method of quality as-
surance of the highly sensitive PCR technique, which
is prone to contaminations (Fig. 5).
Other virological diagnostic techniques, i.e., sero-
logical investigations, are not useful in the context of
myocardial virus persistence, since these analyses do
not specify the organ afflicted by the tentative viral
infection and moreover cannot distinguish biologi-
cally relevant myocardial infections from past infec-
tions. The latter point is of special interest, since
cardiotropic viruses are ubiquitous, and past infec-
tions can be encountered frequently in adults. There-
fore, this non-invasive approach is not suitable for
the detection of a myocardial viral persistence. In
addition, magnetic resonance imaging techniques
are currently unable to detect virus genome in the
myocardium. This approach is only helpful in diag-
nosing late enhancement as an indirect sign of myo-
cardial inflammation and/or fibrosis [18, 28, 38].
n Biopsy based causal therapy strategies
and clinical relevance
(histology, immunohistology, virological analysis)
Based on the new understanding of the pathogenesis
of DCMi, causal treatment strategies have to be im-
plemented. All studies concerning causal treatment
strategies as well as clinical relevance of viral persis-
tence or myocardial inflammation, respectively, must
be based on EMB investigations. So far, all studies
clearly substantiate the indispensable role of EMB
diagnostics in this disease entity.
The prognostic relevance of enteroviral persis-
tence was identified early in the study by Why et al.
[67]. This study demonstrated that the mortality of
patients with chronic impairment of LV function
was significantly increased in the subgroup of pa-
tients with EMB proven diagnosis of myocardial per-
sistence of enteroviral genome compared to virus
negative patients (mortality: 25% versus 4%) over a
mean observation period of 25 months (range, 11 to
50 months) [67]. In addition, a recent trial from
Frustraci et al. showed clearly that in patients with
viral persistence undergoing immunosuppressive
therapy, the mortality was significantly increased
576 Clinical Research in Cardiology, Volume 95, Number 11 (2006)
© Steinkopff Verlag 2006
Fig. 5 PCR, real-time PCR and sequence analysis
of PVB19 in EMBs. a Qualitative proof of PVB19
genomes by nested PCR. b Quantitative assess-
ment of PVB19 viral load by real-time PCR.
Reproduced from [33]
a
b[20]. On the other hand, the therapy concept of immu-
nosuppression in patients with immunohistologically
proven myocardial inflammation and exclusion of vir-
al persistence diagnosed as DCMi demonstrated a sig-
nificant improvement of LV dysfunction due to this
causal EMB-based treatment strategy [69, 70].
This is additional evidence for the relevance of
myocardial viral persistence for the course of the
disease. There is a clear link between viral persis-
tence and progression of LV dysfunction. In a recent
study with a mean follow-up period of 6 months pa-
tients with spontaneous clearance of viral genomes
(n=64 patients) demonstrated a significant improve-
ment of LV function compared to patients with EMB
proven persistence of viral genome in the myocar-
dium (n=108 patients) [35].
Due to these investigations documenting the clin-
ical relevance of viral persistence for disease pro-
gression, a pilot study was initiated to evaluate the
beneficial effect of an antiviral treatment with inter-
feron- in patients with EMB proven persistence of
adenoviral or enteroviral genomes in patients with
chronic impairment of LV function. This pilot study
demonstrated that this causal antiviral therapy strat-
egy leads to a complete (100%) elimination of viral
genomes, paralleled by a significant improvement of
the clinical symptoms as well as a significant im-
provement of LV function [34]. In light of these very
encouraging data, a prospective, multicenter, place-
bo-controlled randomized phase II study (Betaferon®
in Chronic Viral Cardiomyopathy – BICC Trial) with
interferon- was initiated to elucidate the therapeutic
benefit of an antiviral therapy in patients with LV
dysfunction and viral persistence. In the screening
phase of this study all patients with chronic
(>6 months) left ventricular dysfunction (EF ≥30%
to ≤55%) combined with persistent clinical symp-
toms of heart failure (NYHA II and NYHA III) after
exclusion of coronary heart disease were enrolled. In
addition, those patients were included into the treat-
ment phase in whom enterovirus, adenovirus, or
parvovirus B19 were detected and myocarditis ac-
cording to the Dallas criteria in endomyocardial
biopsies had been excluded.
The histological assessment of EMBs has a rele-
vant prognostic and therapeutic impact only in non-
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Fig. 6 Immunohistological aspects of DCMi. a Typical diffuse infiltration pat-
tern of LFA-1+ lymphocytes in DCMi (original magnification ×200). Immuno-
histochemistry was performed using the monoclonal mouse-anti-human LFA-
1 antibody (clone I21/7, Dakocytomation), a horseradish-peroxidase (HRPO)
conjugated polyclonal rabbit-anti-mouse secondary antibody (Dianova) and
3-amino-9-ethyl-carbazole (AEC) as chromogen. Reproduced from [48]. b Fo-
cal CTLs (perforin
+) infiltrates encircling and entering a cardiomyocyte (ar-
rows) suggestive of myocytolysis in DCMi (original magnification ×630). Im-
munohistochemistry was carried out using the monoclonal mouse-anti-hu-
man Perforin antibody (clone dG9, Biozol), a horseradish-peroxidase (HRPO)
conjugated anti-mouse EnVision® antibody (Dakocytomation) and AEC as
chromogen. Reproduced from [47]. c Homogeneous endothelial ICAM-1 abun-
dance in DCMi (original magnification ×200). ICAM-1 expression was de-
tected immunohistochemically using the monoclonal mouse-anti-human
ICAM-1 antibody (clone 6.5B5, Dakocytomation), a horseradish-peroxidase
(HRPO) conjugated polyclonal rabbit-anti-mouse secondary antibody (Dianova)
and AEC as chromogen. Reproduced from [48]
a b
cinfectious forms of acute myocarditis, like giant cell
myocarditis or eosinophilc myocarditis. Without a
histologically based diagnosis of giant cell myocardi-
tis or eosinophilic myocarditis with a known highly
decreased prognosis, implementation of immunosup-
pressive treatment strategies with a clearly docu-
mented positive effect is impossible.
The most profound data on the prognosis and
specific treatment of this rare disease derive from
the Giant Cell Myocarditis Registry with 63 patients.
However, these data are derived from a registry, not
a randomized controlled trial. The median time to
death or cardiac transplantation for all patients was
5.5 months from the onset of symptoms. 70% of the
patients died or required cardiac transplantation
within 1 year, and the overall rate of death or cardi-
ac transplantation was 89%. Treatment with combi-
nations of immunosuppressive agents, but not corti-
costeroids alone, prolonged transplant-free survival
significantly (p=0.001). Treatment with cyclosporine
and steroids, occasionally combined with azathiopr-
ine and/or muromonab-CD3, was associated with a
median survival of 12.6 months compared to
3.0 months compared to those not treated with im-
munosuppressive agents [11]. Cardiac transplanta-
tion remains an ultima ratio treatment option for
giant cell myocarditis patients. However, recurrence
of giant cell myocarditis has been reported. The 39
Giant Cell Myocarditis Registry patients who under-
went heart transplantation had a 71% 5-year surviv-
al, despite a 25% post-transplantation recurrence
rate by histologic EMB investigations [11]. Assist de-
vices may be helpful to bridge giant cell myocarditis
patients to transplantation, with a rate of successful
bridging to transplantation in 78% of the patients,
hence similar to that reported for other ventricular
assist device recipients [1, 7].
Therefore, for a differentiated diagnostic proce-
dure, the complete arsenal of EMB analyses includ-
ing histology and immunohistology for the detailed
diagnosis of myocardial inflammation and molecular
biological techniques for the detection of viral per-
sistence are mandatory for the etiopathogenic differ-
entiation in patients with clinically suspected myo-
carditis in the past and clinically suspected DCM. In
addition, causal treatment strategies can only be in-
itiated after detailed analysis of EMBs concerning
myocardial inflammation and viral persistence.
Causal treatment strategies however should be still
analyzed in controlled trials (e.g., Betaferon® in
Chronic Viral Cardiomyopathy – BICC Trial).
Moreover, we have to point out that for a relevant
diagnostic procedure at least six biopsies have to be
taken in order to be able to perform the extensive
histological, immunohistochemical and virological
analyses in certified laboratories. This necessity of a
relevant number of endomyocardial biopsies is due
to the fact that a sampling error exists for the exact
characterization of myocardial inflammation as well
as viral persistence. To keep the risk of the proce-
dure of taking biopsies as low as possible, it should
only be performed in experienced centers.
n Diagnosis of rare cases of myocardial affection
of storage diseases
Mainly in cases with myocardial affection in the
context of storage diseases (i.e., amyloidosis), specif-
ic histological investigations of EMBs are of decisive
diagnostic and clinical importance (Table 1). Often,
storage diseases show a diffuse pattern of myocardial
affection, and therefore the histological assessment
of the EMBs has a high sensitivity and specificity
[2]. In addition, the storage diseases can be classi-
fied as a form of extracellular space infiltration be-
tween the myocytes (typically seen in amyloidosis)
and a form infiltrating the myocytes (typically seen
in lysosomal storage diseases (M. Fabry) and hemo-
chromatosis). The exact diagnosis of myocardial
storage disease is essential, because there are specific
treatment options especially in Fabry’s disease [6].
This disease is caused by a deficit in the lysosomal
enzyme -galactosidase A (-Gal A). Causal treat-
ment options in Fabry’s disease are an enzyme en-
hancement therapy with galactose infusion [19] or
an enzyme replacement therapy [15]. These treat-
ment strategies have been effective in clearing glyco-
lipid accumulation in myocytes, with an improve-
ment in cardiac function [65]. Cardiac amyloidosis
is characterized by extracellular amyloid infiltration
throughout the heart. The presence of cardiac amy-
loidosis and its relative predominance varies with
the type of amyloidosis. Five different types of amy-
loidosis have been described according to the under-
lying disease. These five forms are immunoglobulin
amyloidosis, hereditary amyloidosis, senile systemic
amyloidosis, secondary amyloidosis due to systemic
inflammation, and hemodialysis-associated amyloi-
dosis. Interestingly, secondary amyloidosis almost
never affects the heart in any clinically significant
manner. The common form of amyloidosis is the
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Table 1 Myocardial storage diseases
Amyloidosis
Lysosomal storage disease (e.g., morbus Gaucher)
Glycogen storage disease (e.g., morbus Pompe)
Glycosphingolipid storage disease (morbus Fabry)
Mucopolysaccharidosis (e.g., morbus Hurler)
Hemochromatosislight-chain precursor amyloidosis (AL amyloidosis),
which belongs to immunoglobulin amyloidosis. The
cardiac involvement in light-chain precursor amyloi-
dosis (AL amyloidosis) ranges from absent to severe
infiltrative forms. AL amyloidosis is associated with
a plasma cell dyscrasia which is related to multiple
myeloma. Once congestive heart failure is present,
the median survival is <6 months in untreated pa-
tients with AL amyloidosis. Therefore, early diagno-
sis and prompt initiation of therapy is essential in
this disease entity. The final diagnosis of cardiac
amyloidosis is based on the results of EMB analysis.
The symptomatic therapy of cardiac AL amyloidosis
is mainly based on high dose diuretics. ACE inhibi-
tors and angiotensin II inhibitors are very poorly
tolerated in subjects with AL amyloidosis. Even
small doses may cause profound hypotension. Also
-blockers may be limited because of refractory
heart failure or disease-related severe hypotension.
Also digoxin is of little value in amyloidosis, and
these patients may be at increased risk of digoxin
toxicity because the drug binds avidly to amyloid fi-
brils. The definitive treatment of AL amyloidosis is
antiplasma cell therapy aimed at stopping the pro-
duction of the paraprotein responsible for the for-
mation of amyloid [16]. This can be achieved by a
number of chemotherapeutic regimens. In selected
cases without progressive heart failure high dose
chemotherapy with autologous stem cell replacement
is also a considerable treatment option. However, in
patients with advanced cardiac disease, peritreat-
ment mortality is high (ca. 30%). An ejection frac-
tion <40% is generally considered an absolute con-
traindication to high dose chemotherapy. In highly
selected patients, cardiac transplantation may also
be considered as a therapeutic approach. However,
because patients with cardiac transplantation dem-
onstrated a high long-term mortality due to disease
progression in the heart and in noncardiac organs as
well, a combined therapy of heart transplantation
and high dose chemotherapy in combination with
stem cell transplantation with the aim to abolish
amyloid production seems to be a future therapeutic
option.
Less well known, and probably less common, is
the cardiac manifestation of light-chain deposition
disease (light-chain cardiomyopathy), which can
mimic AL amyloidosis. The diagnosis of light-chain
cardiomyopathy based on endomyocardial biopsies
can be performed adequately only by using electron
microscopy with antikappa or antilamda immuno-
gold labeling. Concerning treatment options, che-
motherapy targeting the underlying plasma cell dys-
crasia may lead to reversal of the cardiomyopathy.
There are also a number of different hereditary
forms of amyloidosis. In most cases, these hereditary
forms of amyloidosis are due to the production of a
mutant transthyretin protein in the liver. The onset
of the disease occurs from the third decade on, most
commonly after the age of 40. The deposition of
transthyretin affects the myocardium as well as the
conduction system. In addition, in some forms pe-
ripheral neuropathy may predominate. Since the ab-
normal transthyretin in hereditary amyloidosis is
mainly produced by the liver, liver transplantation is
the most important and the only definitive therapeu-
tic intervention [16].
CONTRA
n Lack of evidence based on phase III
therapeutic studies which refer to the results
of endomyocardial biopsy investigations
In patients with clinically suspected acute myocardi-
tis, or histologically proven diagnosis of myocardi-
tis/borderline myocarditis, respectively, no random-
ized phase III trial could demonstrate beneficial ef-
fects of immunosuppression or immunomodulatory
treatment strategies as a causal EMB guided therapy
option. The largest trial so far, the American Myo-
carditis Trial, in which patients with histologically
proven myocarditis/borderline myocarditis according
to the Dallas classification were enrolled without any
analysis concerning the presence of myocardial viral
persistence, did not show any beneficial effect of a
causal immunosuppressive therapy in these patients
[40].
In DCM patients with EMB proven myocardial in-
flammation and/or viral persistence, only small sin-
gle center randomized trials or pilot trials, respec-
tively, could demonstrate positive effects of causal
treatment strategies (immunosuppression in patients
with inflammation and exclusion of viral persistence;
antiviral in patients with viral persistence) in this
disease entity. Concerning the detection of viral per-
sistence – especially of DNA viruses (human herpes
virus type 6) – in the myocardium it has to be taken
into account that the conformation of the viral ge-
nome in the myocardium by molecularbiological as-
says is not necessarily linked to active viral replica-
tion [8]. Therefore the interpretation of DNA virus
persistence has to be handled with care. In addition,
the results of a prospective, multicenter, placebo-
controlled randomized study with interferon- are
still pending. One multicenter trial (Betaferon® in
Chronic Viral Cardiomyopathy - BICC Trial) was in-
itiated in order to elucidate the therapeutic benefit
of antiviral therapy in patients with LV dysfunction
and viral persistence. Depending on the results of
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tients with viral persistence and progressive LV dys-
function has to be discussed. However, there is still
no phase III trial proving any causal therapy concept
[34, 36, 60, 69, 70].
n Spontaneous complete healing of myocarditis
The transition from clinically suspected acute myo-
carditis or histologically proven myocarditis/border-
line myocarditis, respectively, to a chronically pro-
gressive disease with progressive impairment of LV
function is seen only in about 20% of the patients
[13]. This unfavorable course is not predictable by
the histological, immunohistochemical and virologi-
cal findings of the EMB, and can only be evaluated
after a close clinical follow-up concerning the de-
tailed evaluation of clinical symptoms and heart
function (e.g. echocardiography). In addition, the in-
terpretation of EMB results in courses of sponta-
neous healing after an acute viral induced myocardi-
tis has to be done very carefully, because in this
transition period between acute infection and heal-
ing nonfeasible results may be produced, which have
to be controlled in the follow-up period. Therefore
the indication for EMB in patients with clinically
suspected acute myocarditis has to be weighed on a
case-by-case basis. However, especially in patients
with rapid progressive impairment of LV function
despite complete conventional heart failure treat-
ment, in these cases EMB investigations should be
performed to verify the clinically suspected diagno-
sis of acute viral myocarditis or to rule out rare
cases of acute myocarditis, e.g., giant cell myocardi-
tis [7, 10, 11, 14, 23] with good treatment options
[11].
n Age-related limitations for endomyocardial
biopsy investigations
In light of the lack of robust data on the diagnostic
and clinical value of EMB diagnostics in the elderly
(i.e., >75 years), on the one hand, and due to the
limited life expectancy of these patients, as well as
the increasing complexity of polimorbidity often oc-
curring in the elderly, EMB obtainment for diagnos-
tic use has to be considered very carefully, although
myocarditis seems to be quite frequent in elderly pa-
tients. In addition, performing EMBs in the elderly
is technically not more difficult than in younger pa-
tients. However, the occurrence of concomitant dis-
eases as well as the clinical condition of the elderly
patient has to be considered before deciding to per-
form EMB investigations.
Conclusions
In patients with clinically suspected acute myocardi-
tis and progression of disease despite complete heart
failure medication, EMB investigations are indicated.
This approach is necessary for the verification of the
clinically suspected diagnosis of acute viral myocar-
ditis as well as for the diagnosis of rare pathogenic
entities of acute myocarditis (i.e., giant-cell myocar-
ditis, hypersensitivity myocarditis, eosinophilic myo-
carditis) aiming at specific treatment strategies (e.g.,
immunosuppression) at this very early stage of the
disease.
In patients with suspected myocarditis in the past
or DCM, EMB investigations are indicated provided
that the complete arsenal of contemporary EMB ana-
lyses are performed in certified laboratories and if a
progressive deterioration of LV function and/or pro-
gression of heart failure symptoms despite complete
heart failure medication is documented. Contempor-
ary EMB analyses include histological and immuno-
histological analysis for the detailed diagnosis of
myocardial inflammation, and molecular biological
techniques for the detection of viral persistence in-
cluding quantification of the virus load and se-
quence analysis of the amplified viral genomes. Only
this approach enables the elucidation of the underly-
ing pathogenesis and the introduction of causal
treatment modalities, since they strongly depend on
the EMB-based differential diagnosis (Fig. 4).
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